What one share of Nuvectis Pharma holds
We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements.
Nuvectis Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.31 |
|---|---|
| Cash and investments | $0.83 |
| Book value | $0.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$3.02 | — | — | — | −$2.44 |
| 2022 | — | −$1.51 | — | — | $0.00 | $0.94 |
| 2023 | — | −$1.43 | — | — | $0.00 | $0.70 |
| 2024 | — | −$1.11 | — | — | $0.00 | $0.50 |
| 2025 | — | −$1.32 | — | — | $0.00 | $0.72 |
Common questions about Nuvectis Pharma
How much does one share of Nuvectis Pharma earn?
Over the last 12 months, Nuvectis Pharma lost $1.31 for each share.
Does Nuvectis Pharma pay a dividend?
Nuvectis Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Nuvectis Pharma’s book value per share?
Nuvectis Pharma’s book value is $0.34 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Nuvectis Pharma have?
Each share of Nuvectis Pharma has $0.83 of cash and investments, as of June 30, 2026.
Has Nuvectis Pharma bought back shares?
Nuvectis Pharma’s share count rose about 411% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.